TICKERNERD
Menu
MBOTMBOTHealthcare · Medical Devices

MBOT Stock Forecast: Microbot Medical, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.09
−2.68% on the day

The 4 Wall Street analysts covering Microbot Medical, Inc. hold a median 12-month price target of $3.5 — +221.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$75.2M
Ticker Nerd rank
12/ 100
Median analyst target
$3.50
Analysts covering
4
Revenue$105K
Operating income−$4.3M
Net income−$3.7M
Free cash flow−$5.2M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+12.4%
1M
−9.2%
YTD
−45.5%
1Y
−49.5%
From 52W high
−61.8%
From 52W low
+16.0%
$0.94
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MBOT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Microbot Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
12/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
77
Growth
47
Revisions
44
Quality
35
Volatility
34
Accruals
19
Issuance
15
Momentum
9
Value
9

Size (77): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MBOT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MBOT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26MBOTHigh $12.00Median $3.50Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $2.50Median $3.50High $12.00

The green dot is the last close — the median target sits +221.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Oct 2026CitizensInitiatesMarket Outperform$2.50
21 Oct 2026HC Wainwright & Co.ReiteratesBuy$12
14 Aug 2026B. Riley SecuritiesReiteratesBuy$5.00 → $4.00
14 Aug 2026B. Riley SecuritiesReiteratesBuy—
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy$4.00
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy—
14 Apr 2026HC Wainwright & Co.ReiteratesBuy—
10 Feb 2026B. Riley SecuritiesInitiatesBuy—
3 Dec 2025Roth CapitalInitiatesBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
15 Oct 2025HC Wainwright & Co.ReiteratesBuy—
11 Sept 2025HC Wainwright & Co.MaintainsBuy—
10 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Jan 2025HC Wainwright & Co.MaintainsBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.MaintainsBuy—
18 Oct 2023HC Wainwright & Co.ReiteratesBuy—
26 June 2023HC Wainwright & Co.ReiteratesBuy—
6 June 2023HC Wainwright & Co.ReiteratesBuy—
9 May 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MBOT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MBOT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Microbot Medical, Inc. returned −49.5% against +12.4% for the S&P 500, dividends included.

MBOT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26MBOTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MBOT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Microbot Medical, Inc. (MBOT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.7×

Cheaper than 89% of US stocks

Price / sales
210.6×

Cheaper than 3% of US stocks

Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
−0.5×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
1.9%

Higher than 5% of US stocks

Operating margin
−2567.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.9%

Higher than 26% of US stocks

Return on assets
−21.7%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Microbot Medical, Inc. (MBOT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Microbot Medical, Inc. has a market value of $75.2M and an enterprise value of $8.7M.

  • Revenue in the twelve months to 31 Mar 2026: $105K.

  • Net income over the same four quarters: −$14.2M, a −13535.2% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$15.4M, after $155K of capital spending.

  • Shares outstanding: 67.2M.

  • Trailing P/E: −3.7×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Microbot Medical, Inc. employs 43 people — $2K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

MBOT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MBOTMicrobot Medical, Inc.$75.2M12
OMOutset Medical, Inc.$73.7M38
LNSRLENSAR, Inc.$71.7M56
HYPRHyperfine, Inc.$76.1M47
ECORelectroCore, Inc.$67.8M50
SERASera Prognostics, Inc.$79.9M43
LUCDLucid Diagnostics, Inc.$82.2M36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Microbot Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MBOT news & analysis

Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System

GlobeNewsWire · 27 Oct 2026positive

Microbot Medical secured ELMNT IR as the first office-based lab customer for its LIBERTY Endovascular Robotic System. ELMNT IR is also the system’s first West Coast account, extending the company’s geographic reach in line with its Full Market Release strategy.

Why it matters — The customer win adds an office-based lab account and a West Coast presence as the company pursues its Full Market Release strategy.

Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.

GlobeNewsWire · 23 Oct 2026positive

Microbot Medical said executives and commercial team members will attend the SIR EDGE 2026 conference in Louisville, Kentucky. The company said the event will provide an opportunity to engage with prospective customers.

Why it matters — The conference attendance is part of Microbot Medical’s efforts to expand its presence across the U.S. and connect with prospective customers.

Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio

GlobeNewsWire · 20 Oct 2026positive

Microbot Medical was granted multiple new patents, further expanding its global intellectual property portfolio. The company now holds 44 issued patents and 49 pending patents globally, while commercialization advances in U.S. and international markets.

Why it matters — The patent grants and portfolio totals provide MBOT watchers an update on the company’s intellectual property and commercialization progress.

Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel

GlobeNewsWire · 6 Oct 2026positive

Microbot Medical entered a three-year exclusive distribution agreement with Medtechnica Ltd. to distribute the LIBERTY Endovascular Robotic System throughout Israel. The company said the agreement advances its international markets strategy as it prepares for potential future entry outside the U.S.

Why it matters — MBOT watchers may note the agreement as a step toward establishing distribution in a developed market outside the U.S.

Microbot Medical® Highlights Growth Strategy

GlobeNewsWire · 25 Sept 2026neutral

A news item titled "Microbot Medical® Highlights Growth Strategy" was published on GlobeNewsWire, though the excerpt is unavailable due to an HTTP 503 service error, so no content could be retrieved.

Why it matters — MBOT watchers would care because the headline suggests the company is communicating its growth strategy, but the content could not be verified.

FAQ

Frequently asked questions about MBOT stock

What is the MBOT stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Microbot Medical, Inc. have a median 12-month price target of $3.5, with estimates ranging from $2.5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MBOT stock a buy right now?

Of the 4 analysts covering Microbot Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Microbot Medical, Inc. 12 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MBOT?

As at 31 Oct 2026, Microbot Medical, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).

Will MBOT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +221.1% from the last close, and Ticker Nerd's factor model ranks Microbot Medical, Inc. 12 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MBOT stock forecast for 2030?

No analyst covering Microbot Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $12 over the next 12 months.

How has MBOT stock performed over the past year?

Microbot Medical, Inc. returned -49.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Microbot Medical, Inc. do?

Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures.

What is the latest news on MBOT?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System". Microbot Medical secured ELMNT IR as the first office-based lab customer for its LIBERTY Endovascular Robotic System. ELMNT IR is also the system’s first West Coast account, extending the company’s geographic reach in line with its Full Market Release strategy.

Company

About Microbot Medical, Inc.

Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures. Its current product portfolio centers on the LIBERTY Endovascular Robotic System, a disposable robotic platform designed to support catheter-based interventions in cardiovascular, peripheral, endovascular, and neurovascular care. The company also works on robotic endoluminal surgery devices aimed at improving precision and control in complex vascular pathways. Microbot Medical Inc. operates in the healthcare technology and medical devices market, where its systems are intended to help clinicians perform procedures with greater remote control and workflow efficiency. Headquartered in Hingham, Massachusetts, the company concentrates on developing specialized tools for interventional medicine and robotic-assisted procedure delivery.

CEO Mr. Harel Gadot · 43 employees · United States · https://microbotmedical.com